1. Home
  2. GRC vs NUVB Comparison

GRC vs NUVB Comparison

Compare GRC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

HOLD

Current Price

$61.25

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.24

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRC
NUVB
Founded
1933
2018
Country
United States
United States
Employees
N/A
291
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
GRC
NUVB
Price
$61.25
$4.24
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
124.9K
4.5M
Earning Date
04-23-2026
03-02-2026
Dividend Yield
1.22%
N/A
EPS Growth
32.03
N/A
EPS
2.02
N/A
Revenue
$682,389,000.00
N/A
Revenue This Year
$6.62
$190.15
Revenue Next Year
$4.66
$62.54
P/E Ratio
$31.00
N/A
Revenue Growth
3.44
N/A
52 Week Low
$30.87
$1.57
52 Week High
$68.02
$9.75

Technical Indicators

Market Signals
Indicator
GRC
NUVB
Relative Strength Index (RSI) 48.96 36.01
Support Level $56.98 $4.07
Resistance Level $67.61 $5.55
Average True Range (ATR) 2.36 0.21
MACD -0.01 0.04
Stochastic Oscillator 51.50 17.99

Price Performance

Historical Comparison
GRC
NUVB

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: